Endocrine Abstracts

Although most pituitary tumors are benign, some are invasive or aggressive. In the absence of specific markers of malignancy, only tumors with metastases are considered malignant. Recently we identified a marker set of invasion, proliferation and aggressiveness in prolactin (PRL) tumors1. We will present the prognostic value of histological and molecular markers in PRL tumors and their usefulness in other types of pituitary tumors.Forty-five patients, 23...

Context: Differentiating Cushing’s disease (CD) from pseudo-Cushing’s syndrome (PCS) is one of the most challenging problems since no biological test is yet perfect. Almost 30 years ago our group demonstrated the interest of 4 mg i.v. dexamethasone suppressing test (DST) to differentiate obese patients to CD.Objective: To reevaluate the diagnostic accuracy of the 4 mg i.v. DST in carefully selected patients with PCS and CD.<p class="abstext...

Introduction: Pituitary incidentalomas (PIs) defined as pituitary tumors discovered by systematic neuroimaging constitute an increasingly clinical problem. Most of PIs are nonfunctioning tumors (NFPIs) with systematic investigation revealing visual and/or endocrinological impairment in some patients while others remained asymptomatic. If the therapeutic management is well codified for functioning PIs and symptomatic NFPIs, a debate still remain for asymptomatic NFPIs between s...